Author: Zacks Small Cap Research

123457530 / 749 POSTS
By Ian Gilson, PhD, CFANASDAQ:SNES READ THE FULL SNES RESEARCH REPORT SenesTech (NASDAQ:SNES) has reported its 2019 full year results, followed by a conference call, on March 16, 2020. Revenue in the fourth quarter was $0.064 million and this was the ...
By Lisa ThompsonNYSE:DSS READ THE FULL DSS RESEARCH REPORT Impact Biomedical On Friday, Document Security Systems, Inc.’s (NYSE:DSS) stock popped when it announced that it has entered into a binding term sheet to acquire Impact Biomedical, Inc. Impac ...
By David Bautz, PhDNASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Data from Phase 1 Trial of XPro1595 in Alzheimer’s Disease in 2H20 INmune Bio, Inc. (NASDAQ:INMB) is currently conducting a Phase 1 clinical trial of XPro1595 in patien ...
By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) reported revenue below our expectations but gross margins reached a new fourth quarter record. As Marrone gains more experience in biologics ...
By David Bautz, PhDNASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 to be Developed for Severe Pneumonia and ARDS On March 9, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced that based upon preclinical results that were recently p ...
By David Bautz, PhDOTC:VIVXF READ THE FULL VIVXF RESEARCH REPORT Business Update Avivagen, Inc. (OTC:VIVXF) is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promo ...
By Anita Dushyanth, PhDNASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Results of the Phase 2b Trial The primary objective of the Phase II study was to explore therapeutic efficacy in patients and more importantly, determine the dose(s) and regimen fo ...
By David Bautz, PhDNYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Topline Data for Phase 2 Trial of AGO13 in Oral Mucositis in Early 2Q20 Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead developme ...
By David Bautz, PhDNASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Financial Update On March 4, 2020, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced financial results for the fourth quarter and full year 2019. For the fourth quarter of 2019, Opi ...
By Brian Marckx, CFANASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Fiscal Q3 2020 Financials, Operational Update Aethlon (NASDAQ:AEMD) reported fiscal Q3 2020 financial results and provided an operational update. Relative to the latter, which we disc ...
123457530 / 749 POSTS